Introduction {#Sec1}
============

Aggregation of neuronal proteins is a common mechanistic theme in neurodegenerative diseases \[[@CR13]\]. Whether due to point mutations or post-translational modification, normally soluble proteins are altered and form insoluble fibrillar aggregates \[[@CR18]\]. Alzheimer's disease (AD), the most common form of dementia, is characterized pathologically by abundant diffuse and neuritic plaques throughout most cortical regions. Amyloid β-protein (Aβ) is a 39--43 amino acid peptide cleaved from a larger precursor protein (amyloid precursor protein or APP) that deposits extracellularly as senile plaques either as loose, nonfibrillar diffuse plaques, or as a more compacted, fibrillar form, with dystrophic neurites coursing through the plaque \[[@CR25]\]. Other aggregated proteins found in the AD brain include the microtubule-associated protein tau \[[@CR11]\] as neurofibrillary tangles and the presynaptic protein α-synuclein \[[@CR13]\] in the form of Lewy bodies.

The alteration, deposition and aggregation of amyloid proteins may be an ill-fated response to the disease process or themselves lead to a cascade of cellular responses ultimately resulting in neuronal dysfunction and death.

Nonbrain protein aggregates have been described in muscle disease. For example, amyloid-like deposits have been described in inclusion body myositis \[[@CR2]\]. Other protein aggregates found in muscle disease include desmin-related myopathies, actinopathies and myosinopathies \[[@CR30]\]. Aggregates containing these proteins have not been described in brain disease. Another muscle protein associated with myopathy is dysferlin. Dysferlin is a plasma membrane and cytoplasmic vesicle-associated protein implicated in three adult-onset muscle diseases (limb-girdle dystrophy, type 2B, Miyoshi myopathy and distal anterior compartment myopathy)\[[@CR4], [@CR9], [@CR22], [@CR24]\]. Although described in peripheral nerve \[[@CR30]\] and demonstrated by Western blot in human and mouse brain \[[@CR21]\], there is little known about the function of dysferlin in the brain or its role in neurodegenerative disease. We describe the pattern of dysferlin expression in the normal and AD brain and examine dysferlin accumulation in association with amyloid deposition in the brains of AD patients.

Materials and methods {#Sec2}
=====================

Case materials {#Sec3}
--------------

Case materials were derived from research participants in a longitudinal study of healthy aging and dementia who were studied postmortem. The diagnostic criteria are consistent with probable AD reported by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Association \[[@CR26]\] and confirmed by autopsy to meet high probability of AD according to National Institute of Aging-Reagan criteria \[[@CR28]\]. The clinical dementia rating (CDR) was used to determine the presence or absence of dementia and stage its severity \[[@CR27]\]. The global CDR is derived by a synthesis of individual ratings in six cognitive and functional categories where CDR = 0 indicates no dementia and CDR = 0.5, 1, 2, or 3 corresponds to very mild, mild, moderate, or severe dementia \[[@CR27]\]. The CDR is closely correlated with the presence of dementia pathology at autopsy \[[@CR14]\]. The Washington University Human Studies Committee approved all procedures.

Twelve brains were examined. Three cases were rated as nondemented (CDR 0) with a mean age of 87.5 years. Nine AD brains were examined; three each of mild (CDR 1), moderate (CDR 2) and severe (CDR 3). The mean age of the demented cases was 85.9 years with mean disease duration of 8.9 years (Table [1](#Tab1){ref-type="table"}). Control cases were all Braak stage I or II \[[@CR6]\]. Sampling during postmortem exam was done from 29 different cortical, subcortical and brainstem regions. Paraffin-embedded sample for this study were taken from midfrontal, cingulate and entorhinal regions; three sections were stained for each antibody with appropriate controls \[[@CR15]\]. Biochemistry was performed on midfrontal gyrus adjacent to the section taken for immunohistochemistry for each case. Table 1Sample characteristics and findings at postmortem examinationCaseAge (years)SexCDRDisease duration (years)Brain wt (g)Braak scoresCERAD criteriaNIA--Reagan criteriaNeurofibrillaryAmyloid192F0--1,120IIA----285F0--1,100IA----392F0--1,210IA----485F181,200IVCDefiniteHigh599M121,230VBDefiniteHigh695M1141,360VCDefiniteHigh781M216790VICDefiniteHigh891M2111,580VBDefiniteHigh990M271,170IVBDefiniteHigh1086M3101,310VICDefiniteHigh1179F38770VICDefiniteHigh1288M3111,130VICDefiniteHigh

Immunohistochemistry {#Sec4}
--------------------

Immunohistochemistry was done as previously described \[[@CR14], [@CR15]\]. Briefly, serial 6 μm sections of paraformaldehyde-fixed, paraffin-embedded tissue were prepared and incubated overnight at 4°C with antibodies against dysferlin (Novacastra Laboratories), tau (17026, gift from J. Trojanowski), and amyloid β-protein (6E10, Signet). Sections were developed by avidin--biotin complex method (Vector Laboratories) for immunohistochemistry with DAB (brown), Vector Red (pink) and Vector SG (blue) as chromogens. Alexa-Red and Green (Jackson Laboratories) antibodies were used for immunofluorescence. Sections were examined with a Nikon E800 Research microscope, and images were digitized and viewed with AnalySIS analytic software (Soft Imaging Systems, GmbH).

Western blots {#Sec5}
-------------

Western blotting and biochemical fractionation were performed as described previously \[[@CR16]\]. Briefly, two sections of gray matter (0.3 g) from the midfrontal cortex of AD and normal age-matched control brains were dissected from underlying white matter. After dissection, gray matter was divided into two samples (Fig. [1](#Fig1){ref-type="fig"}). One sample was homogenized in RIPA (150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, 50 mM Tris, pH 8, 20 mM, NaF, 2 mM EGTA, 0.5% levamisole, 1 mM NaVO4) to estimate total dysferlin. The other sample was homogenized and subjected to sequential extraction buffers of increasing protein extraction strength. For each buffer, pellets were washed twice and supernatants pooled. Samples were first homogenized in 2 ml/gram of tissue of high-salt (HS) buffer (50 mmol/l Tris, pH 7.4, 750 mmol/l NaCl, 10 mmol/l NaF, 5 mmol/l ethylenediaminetetraacetic acid with protease inhibitors) and centrifuged at 100,000*g* for 30 min. The pellets were re-extracted and the supernatants were pooled. The pellets were sequentially extracted twice with 2 ml/gram of HS buffer/1% Triton X-100 (HS/T) and once with 1 ml/gram sodium dodecyl sulfate (SDS) sample buffer (1% SDS, 10% sucrose, 10 mmol/l Tris, pH 6.8, 1 mmol/l ethylenediaminetetraacetic acid, 40 mmol/l dithiothreitol). The pellets were extracted with 0.67 ml/g 70% formic acid (FA) and disrupted with two sequential 2-s sonication bursts. FA was evaporated in a vacuum centrifuge (Eppendorf). SDS sample buffer (0.67 ml/g) was added to the dried pellets, followed by vigorous vortex, and the pH was adjusted with NaOH. SDS sample buffer was added to the HS and HS/Triton fraction and all of the samples were boiled for 5 min. The FA samples were centrifuged at 13,000*g* for 5 min to remove insoluble debris. Five microliters of each fraction was loaded in separate lanes for SDS-polyacrylamide gel electrophoresis followed by Western blot analysis with antibodies again dysferlin. The immune complexes were visualized with the use of the ECL Plus kit (Amersham) according to the manufacturer's protocol. The autoradiographs obtained were scanned and the band intensity quantified utilizing TotalLab software (Nonlinear Dynamics, Newcastle on Tyne, UK). Statistical analyses were performed by analysis of variance using SPSS statistical software. Fig. 1Schematic representation of sequential protein extraction buffers. Samples are divided into equal portions. The first sample is homogenized in RIPA buffer and blotted to estimate total dysferlin levels. The other sample is homogenized in sequential extraction buffers of increasing protein extraction strength. The first extraction is in high-salt (*HS*) buffer. The supernatants are saved and the pellet is extracted with HS buffer/1% Triton X-100 (HS/T) buffer. After saving the supernatants, the resultant pellet is homogenized in sodium dodecyl sulfate (*SDS*) sample buffer. Resulting pellets are finally extracted with 70% formic acid (*FA*). Supernatants are blotted to estimate differing levels of dysferlin solubility with the HS fraction representing the most soluble phase and the FA fraction representing the most insoluble phase

Results {#Sec6}
=======

Localization of dysferlin in normal (CDR 0) brain {#Sec7}
-------------------------------------------------

Microscopic evaluation of the dysferlin staining in the normal (CDR 0) brain localized expression to the cytoplasm of large pyramidal neurons of layers III, V and VI in the neocortex (Fig. [2](#Fig2){ref-type="fig"}a), layer II neurons of the entorhinal cortex, CA 1--3 neurons in the hippocampus and large projection neurons in the amygdala (not shown). Dysferlin was not localized to astrocytes, endothelial cells or microglia (arrowheads in Fig. [2](#Fig2){ref-type="fig"}b). Little to no dysferlin neuritic staining was seen in control cases (Braak stage I or II). Fig. 2Localization of dysferlin in brains of nondemented subjects. **a**, **b** Demonstrates the localization of dysferlin immunoreactivity in the brain. There is a neuronal expression of dysferlin localized in cytoplasm of large pyramidal (layers III, V, VI) neurons in the frontal cortex at low power (**a**). Little to no neuritic staining was detected. Dysferlin expression is confined to neurons (*arrow*, DAB brown in **b**) and is not seen in glial cells stained with GFAP (*small arrowheads*, Vector Red *pink* in **b**). Magnification of (**a**) is 100× and the *scale bar* in (**a**) = 50 μm. Magnification of (**b**) is 400× and the *scale bar* in (**b**) = 20 μm

Dysferlin in the AD brain {#Sec8}
-------------------------

Dysferlin neuritic accumulation is found throughout the AD brain and in double-label studies it is localized in Aβ neuritic plaques in the neocortex (Fig. [3](#Fig3){ref-type="fig"}a). Double-labeled studies demonstrate co-localization of dysferlin (brown in Fig. [3](#Fig3){ref-type="fig"}b) and Aβ (pink in Fig. [3](#Fig3){ref-type="fig"}b) in the hippocampus. Fig. 3Localization of dysferlin with amyloid pathology in the AD brain. **a**, **b** Demonstrates the location of the dysferlin accumulation in the AD brain with double-labeled studies. **a** Diffuse dysferlin accumulation (DAB, *brown*) and Aβ (DAB-nickel, *black*) in the frontal cortex. Using VectorRed (*pink*, Vector Laboratories) as the chromogen for Aβ and DAB (*brown*, Vector Laboratories) as the chromogen for dysferlin, the pathologic deposition is localized as neuritic pathology in Aβ neuritic plaques in the neocortex hippocampus (**b**). Magnification of (**a**) is 100× and the scale bar in (**a**) = 20 μm. Magnification of (**b**) is 200× and the scale bar in (**b**) = 20 μm

Dysferlin neuritic pathology occurs in conjunction with tau neuritic pathology {#Sec9}
------------------------------------------------------------------------------

In Fig. [4](#Fig4){ref-type="fig"}, we demonstrate that neurites in plaques may comprise tau, dysferlin or both. Triple-labeled studies of midfrontal (Fig. [4](#Fig4){ref-type="fig"}a), cingulate (Fig. [4](#Fig4){ref-type="fig"}b) and entorhinal (Fig. [4](#Fig4){ref-type="fig"}c) cortex illustrate the relationship of tau (pink, arrowheads) and dysferlin (brown, arrows) within an Aβ plaque (blue). Double-labeled immunofluorescent studies (Fig. [4](#Fig4){ref-type="fig"}d--f) demonstrate that tau (green in 4d) and dysferlin (red in Fig. [4](#Fig4){ref-type="fig"}e) have both distinct and overlapping (yellow in Fig. [4](#Fig4){ref-type="fig"}f) epitopes in neuritic plaques. Dysferlin does not appear to co-localize with the more abundant tau dystrophic neurites. Fig. 4Localization of dysferlin with tau pathology in the AD brain. **a**--**f** Demonstrates the location of the dysferlin and tau accumulation in the AD brain with triple-labeled immunohistochemistry studies (**a**--**c**) and double-labeled immunofluorescence studies (**d**--**f**). **a** Midfrontal, **b** cingulate and **c** entorhinal demonstrate tau (Vector Red, *pink*, *arrowheads*), dysferlin (DAB, *brown*, *arrows*) and Aβ (Vector SG, *blue*). Note the distinction between tau-positive and dysferlin-positive structures. Double-labeled immunofluorescence studies demonstrated neurites within amyloid plaques. Neurites may comprise tau (*green*, **d**), dysferlin (*red*, **e**) or overlapping epitopes (*yellow in merged image* of **f**). Magnification of (**a**--**f**) is 600× and the scale bar in (**d**) = 20 μm

Biochemistry {#Sec10}
------------

Western blot analysis following RIPA extraction demonstrated the presence of dysferlin as 230--272 kDa bands in all brains examined (Fig. [5](#Fig5){ref-type="fig"}a); however, there was a decrease in the total dysferlin content in CDR 3 (severe AD) brains compared to CDR 0 (nondemented). There is a progressive decrease in total dysferlin with progressive disease (*r* = 0.998, *P* = 0.001). Western blot analysis following serial extraction of proteins demonstrated a change in the solubility state of dysferlin across the spectrum of dementia (Fig. [5](#Fig5){ref-type="fig"}b). No dysferlin could be demonstrated in the HS fraction. In contrast to the control CDR 0 brains, however, there was a significant reduction of dysferlin in the HS/T fraction in the demented cases (CDR 1 and 2) and was undetectable at the CDR 3 level of severity (*F* = 2,991, *P* \< 0.001). In the SDS-soluble fraction from the demented cases, there was an accumulation of 230--272 kDa bands with dementia progression, that is a more insoluble form of dysferlin was found in severe CDR 3 brains compared to milder stages of dementia (CDR 1) or in nondemented individuals (*F* = 3,183, *P* \< 0.001). Dysferlin did not aggregate or accumulate in the FA-soluble fractions of the control or AD brains. Fig. 5Western Blot analysis of dysferlin in nondemented and AD brains. **a** Nondemented (*CDR 0*) and AD brains (mild = *CDR 1*, moderate = *CDR 2*, and severe = *CDR 3*) were extracted in RIPA as described in the [Materials and methods](#Sec2){ref-type="sec"}. Five microliters of each extraction were loaded into separate lanes of a 12% SDS-polyacrylamide gel electrophoresis and after transfer to nitrocellulose membranes were probed with antibodies against dysferlin. The *blot* demonstrates the presence of dysferlin in both normal and AD brains with declining levels of protein across disease progression. Band intensities were quantified and compared in a bar graph. There is a linear decrease in total dysferlin associated with disease progression (*r* = 0.998, *P* = 0.001). **b** The same brains were sequentially extracted with HS, HS/T, SDS and FA as described in the [Materials and methods](#Sec2){ref-type="sec"} section as loaded onto 12% SDS-polyacrylamide gel electrophoresis as described earlier. Dysferlin was not seen in either the HS or FA fractions. Dysferlin was demonstrated prominently in HS/T fraction in the *CDR 0* brains, with a significant reduction (*F* = 2,991, *P* \< 0.001) of dysferlin in the HS/T fraction in the demented cases (*CDR1* and *2*) and was nearly undetectable in severe AD (*CDR 3*) In contrast, the SDS fraction representing insoluble phases of dysferlin demonstrated significant increases (*F* = 3138, *P* \< 0.001) in the 230--272 kDa bands as dementia progressed from mild (*CDR 1*) to severe (*CDR 3*)

Discussion {#Sec11}
==========

Dysferlin is a new protein described in the AD brain associated with neuritic plaques. Dysferlin is widely expressed in the brain and is found in intracytoplasmic compartments in pyramidal neurons in normal brains. Dysferlin begins to accumulate in dystrophic neurites in the AD brain at mild stages of dementia (CDR 1). Dysferlin is found at all stages of disease with greater accumulation in more advanced disease (CDR 3).

Significantly, our Western blot analysis demonstrated dysferlin in RIPA-extracted fraction in all cases; however, in the serial extracted fractions an alteration in the solubility state of dysferlin was found in demented cases (CDR \> 1) compared with nondemented cases. This coincides with the finding of neuritic pathology by immunohistochemistry. The HS/T fraction represents the transmembrane cytoskeletal fraction of normal dysferlin and decreases with advanced stages of dementia. This may represent the loss of membrane integrity and alteration in cytoskeleton structure. In contrast, the SDS-soluble fraction represents more insoluble forms of the protein suggesting aggregation of dysferlin may be related to disease progression. This alteration of solubility and accumulation is seen in other neurodegenerative diseases (e.g. Parkinson's disease, multiple system atrophy, dementia with Lewy bodies) \[[@CR15], [@CR31]\].

Dysferlin is a member of ferlin family, homologous to fer1 protein in *C. elegans* \[[@CR5]\]. It is highly expressed in muscle but little is known about the role of the protein in the brain. Several members of the ferlin family have been mapped. Dysferlin is found on chromosome 2p13 \[[@CR1]\] and deficiency is associated with three clinical phenotypes: Limb-Girdle muscular dystrophy, type 2B, Miyoshi myopathy and distal anterior compartment myopathy \[[@CR20], [@CR22], [@CR24]\]. Another member of the ferlin family, Otoferlin is mapped to chromosome 2p23 and is associated with autosomal recessive nonsyndromic deafness \[[@CR31]\]. Two other members of the ferlin family have been described: Myoferlin (10q24) \[[@CR7]\] and FerlL4 (20q11) \[[@CR12]\]. Myoferlin is a type II transmembrane protein upregulated in Duchenne muscular dystrophy and may have a role in muscle regeneration and repair \[[@CR10]\]. The function of Fer1L4 is unknown.

Dysferlin is thought to play a role in muscle membrane maintenance and repair \[[@CR3], [@CR4], [@CR9], [@CR12], [@CR19]\]. In *C. elegans*, the Fer1 protein plays a role in vesicle trafficking and membrane fusion and can bind to phospholipids in a calcium-dependent manner \[[@CR22]\]. In dysferlin null-mice, muscle cells are defective in repairing membrane disruptions leading to degeneration \[[@CR4], [@CR21], [@CR23]\]. If dysferlin has a similar membrane repair function in neurons, then it is possible that the deposition of dysferlin in AD may be related to the inability of neurons to repair damage due to accumulating Aβ pathology throughout the progression of AD. The findings reported suggest that there may be common mechanisms of membrane repair in degenerative diseases of muscle (e.g. dystrophinopathies and sarcoglycanopathies) and brain (e.g. AD).

The aggregation of normally soluble proteins in fibrillar lesions is the neuropathologic hallmark of many neurodegenerative diseases. Whether the aggregates or their precursors are the actual toxic species is still under debate \[[@CR8]\]; however, it is likely that the conversion of proteins from a soluble to insoluble state impairs the long-term viability of neurons. In addition, because dysferlin appears to accumulate in conjunction with Aβ deposition and disease progression it may be able to serve as a marker of disease progression. Continued efforts aimed at understanding abnormalities in the misfolding of protein leading to neurodegenerative disease such as Aβ and tau, or proteins associated with aggregation such as dysferlin will provide insights into disease mechanisms underlying neurological disorders characterized by abundant filamentous lesions*.*
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